Table 2: Patients and disease characteristics.

IBD (n=200)CD (n=157)UC (n=41)p-value

Patients’ proportion100%78.50%20.50%

Mean age (years)48.4 ± 13.948.5 ± 14.348.7 ± 12.50.92

Mean length of disease (years)17.3 ± 11.619.1 ± 12.011.3 ± 7.3<0.01

Mean length of follow up (years)4.3 ± 1.84.4 ± 1.95.2 ± 5.90.86

Men, n (%)77 (38.5%)57 (36.3%)17 (41.5%)0.54

≥1 IBD-related intestinal resection, n (%)69 (34.5%)65 (41.4%)3 (7.3%)<0.01

Treatment, n (%)

5-Aminosalicylate, n (%)57 (28.5%)27 (17.3%)29 (70.7%)<0.01

Immunomodulator, n (%)59 (29.5%)52 (33.1%)7 (17.1%)0.05

Biologic agent, n (%)76 (38.0%)70 (44.6%)6 (14.6%)<0.01

Chronic prednisone, n (%)3 (1.5%)3 (1.9%)0 (0%)0.86

Corticosteroids in the last year, n (%)25 (12.5%)22 (14.0%)3 (7.3%)0.25

Access to the provincial register, n (%)163 (81.5%)129 (82.2%)33 (80.4%)0.80

Mean CED (mSv)23.1 ± 45.227.5 ± 49.56.8 ± 14.8<0.01

Exposed to a CED ≥100 mSv, n (%)6 (3%)6 (3.8%)0 (0%)0.20

CD, Crohn’s disease. CED, cumulative effective dose. IBD, intestinal bowel disease. mSv, millisievert. UC, ulcerative colitis.
p value between CD and UC.